PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20465648-9 2010 Slight but significant difference between A/B for p53 with major reduction post isotretinoin [0.66+/-0.31 vs. 0.94+/-0.34 respectively (P = 0.04) was observed. Isotretinoin 80-92 tumor protein p53 Homo sapiens 50-53 9879152-0 1998 13-cis-retinoic acid and interferon-alpha 2a therapy in locally advanced squamous cell carcinoma of the cervix: p53 alteration, proliferating cell nuclear antigen expression and angiogenesis response. Isotretinoin 0-20 tumor protein p53 Homo sapiens 112-115 12488329-7 2003 Moreover, in prostate cancer cells, the synergism between 1,25-(OH)(2)D(3) and 9-cis retinoic acid appears to be dependent on the presence of functional p53; however, 1,25-(OH)(2)D(3)-mediated induction of G(1) cell cycle accumulation and induction of apoptosis is not. Isotretinoin 81-98 tumor protein p53 Homo sapiens 153-156 34224824-5 2021 Isotretinoin is associated with pro-apoptotic signaling in sebaceous glands through upregulated expression of p53, forkhead box O transcription factors (FOXO1, FOXO3), and tumor necrosis factor-related apoptosis inducing ligand (TRAIL). Isotretinoin 0-12 tumor protein p53 Homo sapiens 110-113 9815762-8 1997 High p53 protein expression (LI >/= 0.2) was detected in 25% of the lesions at baseline and in 18% of the lesions after isotretinoin therapy. Isotretinoin 123-135 tumor protein p53 Homo sapiens 5-8 7805028-8 1995 An inverse relationship occurred between the levels of accumulated p53 protein and response to isotretinoin (P = 0.006). Isotretinoin 95-107 tumor protein p53 Homo sapiens 67-70 9815762-13 1997 Eighty-three percent of patients having low p53 expression had up-regulation of RAR-beta mRNA after isotretinoin therapy, compared with 22% of patients with high p53 expression (P = 0.003). Isotretinoin 100-112 tumor protein p53 Homo sapiens 44-47 9815762-14 1997 We correlated baseline p53 protein expression with RAR-beta modulation and clinical responses to isotretinoin therapy. Isotretinoin 97-109 tumor protein p53 Homo sapiens 23-26 9815762-17 1997 The patients with high p53 protein expression and either no change or down-regulation of RAR-beta had a response rate of only 14% to isotretinoin therapy. Isotretinoin 133-145 tumor protein p53 Homo sapiens 23-26 34224824-6 2021 Two literature searches including clinical and experimental studies respectively support the hypothesis that isotretinoin s toxicological mode of action on the pituitary-ovarian axis might be caused by over-expressed p53/FOXO1 signaling resulting in gonadotropin suppression and granulosa cell apoptosis. Isotretinoin 109-121 tumor protein p53 Homo sapiens 217-220 30240097-2 2018 It has been hypothesized that upregulation of nuclear FoxO transcription factors and p53 mediate isotretinoin-induced sebocyte apoptosis in vivo. Isotretinoin 97-109 tumor protein p53 Homo sapiens 85-88 28927457-2 2017 All-trans retinoic acid (ATRA) and isotretinoin (13-cis retinoic acid) enhance p53 expression. Isotretinoin 35-47 tumor protein p53 Homo sapiens 79-82 28927457-2 2017 All-trans retinoic acid (ATRA) and isotretinoin (13-cis retinoic acid) enhance p53 expression. Isotretinoin 49-69 tumor protein p53 Homo sapiens 79-82 28927457-7 2017 p53 induces FoxO1, FoxO3, p21 and sestrin 1, sestrin 2, and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), the key inducer of isotretinoin-mediated sebocyte apoptosis explaining isotretinoin"s sebum-suppressive effect. Isotretinoin 145-157 tumor protein p53 Homo sapiens 0-3 28927457-7 2017 p53 induces FoxO1, FoxO3, p21 and sestrin 1, sestrin 2, and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), the key inducer of isotretinoin-mediated sebocyte apoptosis explaining isotretinoin"s sebum-suppressive effect. Isotretinoin 197-209 tumor protein p53 Homo sapiens 0-3 30144329-7 2018 Isotretinoin enhanced FoxO1, p53 and p21 but inhibited p-FoxO1 and involucrin expression in HPKs. Isotretinoin 0-12 tumor protein p53 Homo sapiens 29-32